Study finds HPV vaccine effective against precancerous cervical lesions
A new study published in The Lancet depicts that GlaxoSmithKline’s human papillomavirus (HPV) vaccine is highly effective at preventing precancerous cervical lesions that can lead to cervical cancer. The researchers said that the HPV-16/18 AS04-adjuvanted vaccine was as much as 98% effective against HPV-16/18, and between 37% and 54% effective against 12 other cancer-causing HPV types.

After two years of its approval, the Advisory Committee on Immunization Practices has detected no major problems with the safety of the HPV vaccine, Gardasil. The vaccine is used to protect against infection caused by the sexually transmitted virus, the HPV, that leads to genital warts and cervical cancer. The Center for Disease Control and Prevention has recommended the vaccination of girls at the age of 11 (much before they turn sexually active). No serious side effects have been found.
New data from an extended follow-up study show that
New data related to